Another study using a pan-HDAC inhibitor, sodium phenylbutyrate, showed that it sensitizes the response of HPV-negative HNSCC cells to cisplatin and that this was mediated through disruption of the Fanconi anemia (FA)/breast cancer susceptibility protein (BRCA) pathway. Here, HDAC9 is linked to head and neck squamous cell carcinoma.